Azathioprine Versus Corticosteroids in Parthenium Dermatitis
Paraules clau
Resum
Descripció
Detailed research plan Clinical evaluation About 60 clinically diagnosed adult patients having Parthenium dermatitis will be taken up for the study. Pregnant females and lactating mothers will be excluded. All the patients will be patch tested with the standardised aqueous extract of Parthenium hysterophorus to confirm the diagnosis and those showing positive patch test reactions to standardised extract will be tested further with serial dilutions of the antigens to determine the titre of contact hypersensitivity (TCH).20 Antibodies do not have any role in this disease therefore the estimation of immunoglobulins will not be done. The diagnosis will be done by patch test. It will be a randomised, clinically study where the patients will be randomly treated with azathioprine 300 mg per week or azathioprine 100 mg a day orally along with topical clobetasol propionate 0.05% w/w and oral cetirizine hydrochloride 10 mg daily for symptomatic relief. No other drugs including the medicines of alternate system will be given for the dermatitis. Clinical evaluation of the patients will be undertaken every four weeks. This will be continued for six months. After 6 months the treatment will be stopped and the patients will be followed up for another 6 months. The graphic record of the disease activity and the treatment will be maintained. In addition, each patient will be evaluated for the side effects of these regimens clinically as well as by the laboratory parameters as per the proforma enclosed, especially haemoglobin, total blood count, differential count, platelets, serum bilirubin, serum alkaline phosphate, serum transaminases, serum electrolytes, serum creatinine, blood urea, blood sugar, urine routine and microscopy and stool examination for occult blood. These tests will be carried out before starting the therapy and then repeated every month during the follow up period. Chest X-ray electrocardiogram and TCH will also be done before the therapy and then at six months unless otherwise required. At the end of the study period, a final evaluation based on the change in severity of the dermatitis, changes in the titre of contact hypersensitivity and the side effects of the drugs will be made. Statistical analysis using chi-square test will be done.
Dates
Darrera verificació: | 04/30/2008 |
Primer enviat: | 09/11/2005 |
Inscripció estimada enviada: | 09/11/2005 |
Publicat per primera vegada: | 09/18/2005 |
Última actualització enviada: | 05/05/2008 |
Publicació de l'última actualització: | 05/07/2008 |
Data d'inici de l'estudi real: | 01/31/2003 |
Data estimada de finalització primària: | 09/30/2005 |
Data estimada de finalització de l’estudi: | 12/31/2005 |
Condició o malaltia
Intervenció / tractament
Drug: azathioprine and corticosteroids for Parthenium dermatitis
Fase
Criteris d'elegibilitat
Edats elegibles per estudiar | 18 Years Per a 18 Years |
Sexes elegibles per estudiar | All |
Accepta voluntaris saludables | Sí |
Criteris | Inclusion Criteria: - All adult patients having ABCD, as shown by the clinical manifestations and positive patch tests with Parthenium, who are willing to participate in the study. Exclusion Criteria: - Patients below the age of 18 years - Pregnant and lactating women. - Patients whose baseline investigations reveal hematological abnormalities or abnormalities of liver or renal function. |
Resultat
Mesures de resultats primaris
1. Clinical remission and side effects [undefined]
Mesures de resultats secundaris
1. Duration of remission [undefined]